Propionic Acid for Multiple Sclerosis: Safety and Benefits

Propionic Acid in Multiple Sclerosis: Safety, Tolerability and Clinical Outcomes From the Pro-MADAI Study

CompletedNot a drug-phase studyMS (type not specified)NCT07595081

We could not find results for this trial

What it found

No results found

We found no results in the registry or in papers.

This trial finished 18 months ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Propionic acid

What it measured

Main measures

  • Safety and tolerability

    9 months

    Safety

Other measures (7)

  • Symbol Digit Modalities Test (SDMT)

    9 months

    Thinking and memory

  • Nine-Hole Peg Test (9HPT)

    9 months

    Disability progressionArm and hand function

  • 10-Meter Walk Test (10mWT)

    9 months

    Walking and mobilityBladder, bowel and sexual function

  • Short Form Health Survey (SF-36)

    9 months

    PainQuality of life (reported by participants)

  • Fatigue Scale for Motor and Cognitive Functions (FSMC)

    9 months

    Thinking and memoryFatigue

  • Epworth Sleepiness Scale (ESS)

    9 months

    Walking and mobilityMood and sleep

  • Beck Depression Inventory-II (BDI-II)

    9 months

    FatigueMood and sleep

Who could take part

MS (type not specified) · 18 to 70

Show the full criteria

Inclusion criteria

* Diagnosis of multiple sclerosis (MS) * Clinically and radiologically stable MS in the previous 3 months * Age between 18 and 70 years * Positive finding for oligoclonal bands (OCBs) * Written consent * Blood collection at the beginning and end of the study for routine parameter examination as well as sample preservation (especially for measuring propionic acid levels) * Negative pregnancy test for female participants of childbearing age

Exclusion criteria

* History of ongoing propionic acid (PA) supplementation exceeding 3 months * Positive JC virus titer during natalizumab treatment * Presence of severe active systemic disease * Presence of acute neurological conditions

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).

Papers

Loading reviews and guidelines…

History

    1. Started

      Aug 2024

    2. Main results due

      May 2025

    3. Finished

      Dec 2025

    Assembled by software from public sources.